Mipomersen |CAS 1000120-98-8|DC Chemicals

Cas No.:	1000120-98-8
Chemical Name:	Mipomersen
Synonyms:	ISIS 301012 free base
Formula:	C₂₃₀H₃₂₄N₆₇O₁₂₂P₁₉S₁₉
M.Wt:	7177.14645999996
Purity:	>95%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Target:	APO B-100
In Vivo:	Mipomersen (25 mg/kg; i.p., twice weekly for 11 weeks) affects levels of h-apoB, h-apoB-100, Lp(a) and OxPL/h-apoB.
In Vitro:	Mipomersen (800 and 1000 μg/mL; 72 hours) reduces 80%-85% intracellular HCV RNA in Huh7/CD81 WT cells with HCVcc (JFH1) infection.

Cat. No.	Product name	Field of application
DC67234	CPG-1018
DC67028	Pegaptanib
DC67027	Onpattro
DC67025	Mipomersen	Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH). The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Mipomersen sodium) that retains the same biological activity.
DC67024	Inotersen	Inotersen is an antisense oligonucleotide that inhibits hepatic production of transthyretin (TTR). The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Inotersen sodium) that retains the same biological activity.
DC67023	Amvuttra
DC72286	Fomivirsen	Fomivirsen (ISIS-2922 free base) is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen binds to and degrades the mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation.
DC47310	Rovanersen	Rovanersen (WVE-120101) is an antisense oligonucleotide that can be used for huntington’s disease research.
DC47308	Lumasiran	Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
DC47306	ARO-AAT	ARO-AAT is a second-generation RNAi drug. ARO-AAT consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade AAT mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes.